Lantheus (NASDAQ:LNTH) Sets New 1-Year High – Time to Buy?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as $107.99 and last traded at $105.03, with a volume of 1423657 shares trading hands. The stock had previously closed at $104.67.

Analyst Ratings Changes

Several brokerages recently commented on LNTH. Mizuho increased their price objective on shares of Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Jefferies Financial Group reaffirmed a “buy” rating and set a $110.00 price target on shares of Lantheus in a research note on Tuesday, March 17th. B. Riley Financial reaffirmed a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. Truist Financial reaffirmed a “buy” rating and set a $115.00 price target (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Price Performance

The company’s 50 day moving average price is $91.83 and its 200-day moving average price is $77.43. The stock has a market cap of $6.84 billion, a P/E ratio of 25.31 and a beta of -0.03. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 4.39 earnings per share for the current year.

Hedge Funds Weigh In On Lantheus

Hedge funds have recently bought and sold shares of the company. M&T Bank Corp bought a new position in shares of Lantheus during the 4th quarter worth about $370,950,000. Farallon Capital Management LLC grew its holdings in shares of Lantheus by 56.1% during the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after buying an additional 1,950,252 shares during the last quarter. Norges Bank acquired a new position in shares of Lantheus during the fourth quarter valued at about $76,197,000. Freestone Grove Partners LP grew its holdings in shares of Lantheus by 4,114.8% during the fourth quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock valued at $40,497,000 after buying an additional 594,088 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Lantheus by 686.1% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock valued at $45,423,000 after buying an additional 522,678 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.